Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 05 November 2013 | By Alexander Gaffney, RAC,
Even outside of the United States, drug shortages are proving to be a stubborn problem, and for reasons similar to those causing chronic shortages of essential medications in the US.
In the US, regulators and analysts say no one problem is to blame for ongoing drug shortages, which have hit sterile injectable drugs particularly hard in recent years. Instead, they say, five problems share portions of blame. Among them:
In response to these challenges, FDA has taken a number of actions intended to mitigate the effects of drug shortages over the course of the last year. Among them:
But as it turns out, the US isn't the only place experiencing drug shortages. As Focus has previously reported, Canada has been experiencing severe shortages as well, causing it to accelerate approvals, consider calls for new regulation and policies, and to allow unapproved drugs into the country.
And in the EU, the European Medicines Agency (EMA) has been dealing with drug shortages of its own, ones which mirror many of the issues seen in the US but also reflect the unique political structure of the EU, such as parallel import of medicines from lower-cost countries to those with more economic purchasing power.
But as in the US, the majority of problems seem to be related to quality manufacturing.
In November 2012, EMA sounded the alarm about "product supply shortages" caused by quality manufacturing problems, saying a lack of medicines could harm patients by disrupting treatments or by leading them to less-effective or less-safe alternatives.
In a reflection paper released at the time, EMA observed that global supply chains, a lack of alternatives for some medications, industry's reactive approach to problems and difficulties with coordinating responses with other regulators had all contributed to drug shortages.
EMA laid out a 13-point plan to address the shortages, of which 10 were short-term actions and the rest medium-term.
The first two of those actions were related to establishing catalogues of drug products authorized for use in the EU that have or are experiencing drug shortages. EMA said an internal catalogue of those products would "facilitate future analysis of trends and communication on shortages," while a public catalogue of current shortages would permit the sharing of data amongst EU regulators and the public.
Now, a year after that paper was released, EMA has announced the launch of that public catalogue. In a 4 November 2013 posting on its website, EMA said any medicine in shortage in more than one member state would be contained within the catalogue.
The catalogue will provide information about the reason for the drug shortage, its current status, the extent of the shortage, how patients and healthcare professionals should respond, and provide links to any relevant documents.
FDA currently maintains a similar list on its website which includes information about the company, the product(s) affected, contact information for the company, expected end of the shortage, reason for the shortage and related information.
EMA Announcement
EMA Drug Shortage Catalogue
EMA 2012 Drug Shortage Reflection Paper
Tags: Drug Shortages, Shortage, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.